Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients.

ABSTRACT:

Introduction

Alopecia areata (AA) is an immune disease characterized by non-scarring hair loss. With the increasing use of Janus kinase (JAK) inhibitors in immune-related conditions, their potential role in AA treatment is gaining attention. Deuruxolitinib has emerged as a potential treatment for moderate to severe AA. This is the first systematic review and meta-analysis that aims to assess the efficacy of deuruxolitinib in moderate to severe AA.

Methods

We systematically searched Cochrane Central Register of Controlled Trials (CENTRAL), Medline, and ClinicalTrials.gov for relevant data. Deuruxolitinib vs. placebo was evaluated, and efficacy was measured using severity of alopecia tool (SALT) and Hair Satisfaction Participants Reported Outcome (SPRO), with the primary time

SUBMITTER: Kalantan M 

PROVIDER: S-EPMC12539349 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature